All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
|
Key learnings |
In older patients receiving a modified pediatric-inspired chemotherapy regimen including PEG-ASP or EC-ASP, 61% of patients experienced Grade III-IV adverse events (AEs); the most prevalent AEs were thrombosis (35.6%), febrile neutropenia (38.4%), and transaminitis (34.2%). |
Median overall survival (OS) was 54 months (95% confidence interval (CI), > 23.7), and the leukemia-free (LFS) survival at 4 years was 48% (95% CI, 33.7–60.6). |
The type of ASP was not significantly associated with OS, LFS or early mortality, but AEs were higher with PEG-ASP vs EC-ASP; male sex and high PEG-ASP dose were identified as significant independent factors for thrombotic events. |
Older age (≥ 70 years), increased white blood cell count at presentation, previous diagnosis of malignancy, and positive measurable residual disease status post-induction therapy were found to be significantly associated with worse OS. |
An ASP-centered pediatric-inspired chemotherapy protocol can be an effective and well-tolerated therapeutic option for older patients with Ph- ALL when used alongside with diligent monitoring and follow-up. |
Subscribe to get the best content related to ALL delivered to your inbox